CAL
ACHV icon

Capital Analysts LLC’s Achieve Life Sciences ACHV Stock Holding History

Capital Analysts LLC’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5K Hold
700
– – ﹤0.01% 1378
2026
Q1 		$2K Hold
700
– – ﹤0.01% 1441
2025
Q4 		$3K Buy
700
+190
+37% +$828 ﹤0.01% 1376
2025
Q3 		$2K Buy
+510
New +$1.4K ﹤0.01% 1365

Other funds holding ACHV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Capital Analysts LLC's ACHV Position: Q2 2026 in Review

Capital Analysts LLC held its Achieve Life Sciences (ACHV) position steady in Q2 2026 at 700 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1378.

Capital Analysts LLC first reported a position in ACHV in Q3 2025 and has held it in 4 quarters since. 111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • Capital Analysts LLC held 700 shares of Achieve Life Sciences worth $5K as of Q2 2026.
  • Capital Analysts LLC left its Achieve Life Sciences share count unchanged in Q2 2026.
  • Achieve Life Sciences made up ﹤0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #1378 holding.
  • Capital Analysts LLC first reported a position in Achieve Life Sciences in Q3 2025 and has held it in 4 quarters since.
  • 111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.